🔮 OOTWOracle · All predictions · Odds sheet · Track record · Benchmark

DEA maintains Schedule I status for psilocybin and MDMA through October 2026 with no approved rescheduling petition

Predicted 2026-04-30 · Resolves 2026-10-30 · legislation · USA
88%
ORACLE CONFIDENCE
⏳ Pending
Every outcome is scored publicly in the ledger.

The DEA (US drug enforcement agency) almost certainly will not change the legal status of magic mushrooms or MDMA in the next six months. That's because no approved medicine using these drugs exists yet, and rescheduling requires years of bureaucratic work.

DEA rescheduling requires either an HHS recommendation or a petitioner-initiated process that historically takes years. FDA declined to approve MDMA-assisted therapy in 2024; psilocybin has no pending NDA. Without an approved NDA or extraordinary political intervention, DEA has no administrative trigger to reschedule. The six-month window is far too short for a rescheduling petition to complete notice-and-comment rulemaking. Resolves YES if both substances remain Schedule I on October 30, 2026.

5 new falsifiable predictions, every day at 12:05 PM ET.
Get tomorrow's Oracle →